{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import numpy as np\n",
    "import sys\n",
    "import os"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "ourdata = pd.read_csv('data/drug_riskscores.csv')\n",
    "ourdata['drug'] = ourdata['drug'].str.lower()\n",
    "drugs = list(ourdata['drug'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "from calc_relative_risks_drugs import *"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Drug target 1,25(oh)2d3 not found. Exiting ...\n",
      "\n",
      "Drug target 17-hydroxyprogesterone not found. Exiting ...\n",
      "\n",
      "Drug target 18f-flutemetamol not found. Exiting ...\n",
      "\n",
      "Drug target 2-hydroxysuccinaldehyde not found. Exiting ...\n",
      "\n",
      "Drug target 4-ap not found. Exiting ...\n",
      "\n",
      "Drug target 4-methylpyrazole not found. Exiting ...\n",
      "\n",
      "Drug target 5-asa not found. Exiting ...\n",
      "\n",
      "Drug target 5-fu not found. Exiting ...\n",
      "\n",
      "Drug target 5-aminolevulinic not found. Exiting ...\n",
      "\n",
      "Drug target 5-aza-2'-deoxycytidine not found. Exiting ...\n",
      "\n",
      "Drug target 5-azacytidine not found. Exiting ...\n",
      "\n",
      "Drug target a77 not found. Exiting ...\n",
      "\n",
      "Drug target acth(1-39 not found. Exiting ...\n",
      "\n",
      "Drug target amd3100 not found. Exiting ...\n",
      "\n",
      "Drug target an2690 not found. Exiting ...\n",
      "\n",
      "Drug target abarelix not found. Exiting ...\n",
      "\n",
      "Drug target anidulafungin not found. Exiting ...\n",
      "\n",
      "Drug target bcnu not found. Exiting ...\n",
      "\n",
      "Drug target benicar-hct not found. Exiting ...\n",
      "\n",
      "Drug target bivalirudin not found. Exiting ...\n",
      "\n",
      "Drug target cas not found. Exiting ...\n",
      "\n",
      "Drug target cgp not found. Exiting ...\n",
      "\n",
      "Drug target cancidas not found. Exiting ...\n",
      "\n",
      "Drug target carfilzomib not found. Exiting ...\n",
      "\n",
      "Drug target colimycin not found. Exiting ...\n",
      "\n",
      "Drug target d-penicillamine not found. Exiting ...\n",
      "\n",
      "Drug target dfmo not found. Exiting ...\n",
      "\n",
      "Drug target enfuvirtide not found. Exiting ...\n",
      "\n",
      "Drug target eptifibatide not found. Exiting ...\n",
      "\n",
      "Drug target famp not found. Exiting ...\n",
      "\n",
      "Drug target fk463 not found. Exiting ...\n",
      "\n",
      "Drug target fty720 not found. Exiting ...\n",
      "\n",
      "Drug target fe(iii not found. Exiting ...\n",
      "\n",
      "Drug target forteo not found. Exiting ...\n",
      "\n",
      "Drug target ge-132 not found. Exiting ...\n",
      "\n",
      "Drug target goserelin not found. Exiting ...\n",
      "\n",
      "Drug target histrelin not found. Exiting ...\n",
      "\n",
      "Drug target hoe not found. Exiting ...\n",
      "\n",
      "Drug target humalog not found. Exiting ...\n",
      "\n",
      "Drug target ici not found. Exiting ...\n",
      "\n",
      "Drug target implanon not found. Exiting ...\n",
      "\n",
      "Drug target insulin not found. Exiting ...\n",
      "\n",
      "Drug target k779 not found. Exiting ...\n",
      "\n",
      "Drug target l-dmp not found. Exiting ...\n",
      "\n",
      "Drug target l-threo-dops not found. Exiting ...\n",
      "\n",
      "Drug target lmwh not found. Exiting ...\n",
      "\n",
      "Drug target ly146032 not found. Exiting ...\n",
      "\n",
      "Drug target lantus not found. Exiting ...\n",
      "\n",
      "Drug target leuprorelin not found. Exiting ...\n",
      "\n",
      "Drug target lisinopril not found. Exiting ...\n",
      "\n",
      "Drug target lovaza not found. Exiting ...\n",
      "\n",
      "Drug target lu not found. Exiting ...\n",
      "\n",
      "Drug target lyxumia not found. Exiting ...\n",
      "\n",
      "Drug target mdv3100 not found. Exiting ...\n",
      "\n",
      "Drug target meropenem not found. Exiting ...\n",
      "\n",
      "Drug target metrodin not found. Exiting ...\n",
      "\n",
      "Drug target mndpdp not found. Exiting ...\n",
      "\n",
      "Drug target n-acetylcysteine not found. Exiting ...\n",
      "\n",
      "Drug target nafarelin not found. Exiting ...\n",
      "\n",
      "Drug target novolog not found. Exiting ...\n",
      "\n",
      "Drug target nuvocid not found. Exiting ...\n",
      "\n",
      "Drug target octreotide not found. Exiting ...\n",
      "\n",
      "Drug target oestrogen not found. Exiting ...\n",
      "\n",
      "Drug target optison not found. Exiting ...\n",
      "\n",
      "Drug target org not found. Exiting ...\n",
      "\n",
      "Drug target pci-32765 not found. Exiting ...\n",
      "\n",
      "Drug target pep005 not found. Exiting ...\n",
      "\n",
      "Drug target pge1 not found. Exiting ...\n",
      "\n",
      "Drug target pge2 not found. Exiting ...\n",
      "\n",
      "Drug target photofrin not found. Exiting ...\n",
      "\n",
      "Drug target promacta not found. Exiting ...\n",
      "\n",
      "Drug target refludan not found. Exiting ...\n",
      "\n",
      "Drug target revasc not found. Exiting ...\n",
      "\n",
      "Drug target romidepsin not found. Exiting ...\n",
      "\n",
      "Drug target som230 not found. Exiting ...\n",
      "\n",
      "Drug target su5416 not found. Exiting ...\n",
      "\n",
      "\n",
      "Drug target signifor not found. Exiting ...\n",
      "\n",
      "Drug target stalevo not found. Exiting ...\n",
      "\n",
      "Drug target supremon not found. Exiting ...\n",
      "\n",
      "Drug target tmc207 not found. Exiting ...\n",
      "\n",
      "Drug target tmc435 not found. Exiting ...\n",
      "\n",
      "Drug target tr-700 not found. Exiting ...\n",
      "\n",
      "Drug target tadenan not found. Exiting ...\n",
      "\n",
      "Drug target triptorelin not found. Exiting ...\n",
      "\n",
      "Drug target udca not found. Exiting ...\n",
      "\n",
      "Drug target vacv not found. Exiting ...\n",
      "\n",
      "Drug target vancocine not found. Exiting ...\n",
      "\n",
      "Drug target vitrum not found. Exiting ...\n",
      "\n",
      "Drug target westcort not found. Exiting ...\n",
      "\n",
      "Drug target abacavir not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó abiraterone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: progesterone with relative risk of -7.060 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: mitotane with relative risk of -8.263 of abiraterone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó acamprosate *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: rufinamide with relative risk of -4.489 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: gabapentin with relative risk of -33.626 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: gabapentin with relative risk of -33.626 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: gabapentin with relative risk of -33.626 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: gabapentin with relative risk of -33.626 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: gabapentin with relative risk of -33.626 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: gabapentin with relative risk of -33.626 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: gabapentin with relative risk of -33.626 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: atomoxetine with relative risk of -44.318 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: atomoxetine with relative risk of -44.318 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: atomoxetine with relative risk of -44.318 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: atomoxetine with relative risk of -44.318 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: atomoxetine with relative risk of -44.318 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: atomoxetine with relative risk of -44.318 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: atomoxetine with relative risk of -44.318 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: felbamate with relative risk of -49.105 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: felbamate with relative risk of -49.105 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: felbamate with relative risk of -49.105 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: felbamate with relative risk of -49.105 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: felbamate with relative risk of -49.105 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: felbamate with relative risk of -49.105 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: felbamate with relative risk of -49.105 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: olanzapine with relative risk of -87.866 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: olanzapine with relative risk of -87.866 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: olanzapine with relative risk of -87.866 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 26: olanzapine with relative risk of -87.866 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 27: olanzapine with relative risk of -87.866 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 28: olanzapine with relative risk of -87.866 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 29: olanzapine with relative risk of -87.866 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 30: olanzapine with relative risk of -87.866 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 31: olanzapine with relative risk of -87.866 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 32: olanzapine with relative risk of -87.866 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 33: olanzapine with relative risk of -87.866 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 34: olanzapine with relative risk of -87.866 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 35: olanzapine with relative risk of -87.866 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 36: olanzapine with relative risk of -87.866 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 37: olanzapine with relative risk of -87.866 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 38: olanzapine with relative risk of -87.866 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 39: amoxapine with relative risk of -89.508 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 40: amoxapine with relative risk of -89.508 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 41: amoxapine with relative risk of -89.508 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 42: amoxapine with relative risk of -89.508 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 43: amoxapine with relative risk of -89.508 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 44: amoxapine with relative risk of -89.508 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 45: amoxapine with relative risk of -89.508 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 46: amoxapine with relative risk of -89.508 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 47: amoxapine with relative risk of -89.508 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 48: amoxapine with relative risk of -89.508 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 49: amoxapine with relative risk of -89.508 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 50: amoxapine with relative risk of -89.508 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 51: amoxapine with relative risk of -89.508 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 52: amoxapine with relative risk of -89.508 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 53: amoxapine with relative risk of -89.508 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 54: amoxapine with relative risk of -89.508 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 55: topiramate with relative risk of -91.841 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 56: topiramate with relative risk of -91.841 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 57: topiramate with relative risk of -91.841 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 58: topiramate with relative risk of -91.841 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 59: topiramate with relative risk of -91.841 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 60: topiramate with relative risk of -91.841 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 61: topiramate with relative risk of -91.841 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 62: topiramate with relative risk of -91.841 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 63: topiramate with relative risk of -91.841 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 64: topiramate with relative risk of -91.841 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 65: topiramate with relative risk of -91.841 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 66: topiramate with relative risk of -91.841 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 67: topiramate with relative risk of -91.841 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 68: topiramate with relative risk of -91.841 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 69: topiramate with relative risk of -91.841 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 70: topiramate with relative risk of -91.841 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 71: flumazenil with relative risk of -116.695 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 72: flumazenil with relative risk of -116.695 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 73: flumazenil with relative risk of -116.695 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 74: flumazenil with relative risk of -116.695 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 75: flumazenil with relative risk of -116.695 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 76: flumazenil with relative risk of -116.695 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 77: flumazenil with relative risk of -116.695 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 78: flumazenil with relative risk of -116.695 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 79: flumazenil with relative risk of -116.695 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 80: flumazenil with relative risk of -116.695 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 81: flumazenil with relative risk of -116.695 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 82: flumazenil with relative risk of -116.695 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 83: flumazenil with relative risk of -116.695 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 84: flumazenil with relative risk of -116.695 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 85: flumazenil with relative risk of -116.695 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 86: flumazenil with relative risk of -116.695 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó acebutolol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: olanzapine with relative risk of -6.163 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: loxapine with relative risk of -6.589 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: cabergoline with relative risk of -7.059 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: dronedarone with relative risk of -7.111 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 5: amiodarone with relative risk of -8.446 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 6: pindolol with relative risk of -8.446 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 7: propafenone with relative risk of -8.669 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 8: penbutolol with relative risk of -8.669 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 9: sotalol with relative risk of -8.956 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 10: carvedilol with relative risk of -8.956 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 11: labetalol with relative risk of -8.956 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 12: mirabegron with relative risk of -8.956 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: nadolol with relative risk of -8.956 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 14: propranolol with relative risk of -9.362 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 15: metoprolol with relative risk of -9.362 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 16: betaxolol with relative risk of -9.362 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease\n",
      "Rank 17: indacaterol with relative risk of -9.362 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: timolol with relative risk of -9.362 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease\n",
      "Rank 19: nebivolol with relative risk of -10.054 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 20: esmolol with relative risk of -10.054 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 21: bisoprolol with relative risk of -10.054 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target acetaminophen not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó acitretin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bexarotene with relative risk of -24.346 of acitretin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bexarotene with relative risk of -24.346 of acitretin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: bexarotene with relative risk of -24.346 of acitretin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: tazarotene with relative risk of -32.793 of acitretin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Psoriasis,dermatology\n",
      "Rank 5: tazarotene with relative risk of -32.793 of acitretin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Psoriasis,dermatology\n",
      "Rank 6: tazarotene with relative risk of -32.793 of acitretin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Psoriasis,dermatology\n",
      "Rank 7: tazarotene with relative risk of -32.793 of acitretin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Psoriasis,dermatology\n",
      "Rank 8: adapalene with relative risk of -50.418 of acitretin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "Rank 9: adapalene with relative risk of -50.418 of acitretin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "Rank 10: adapalene with relative risk of -50.418 of acitretin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "Rank 11: adapalene with relative risk of -50.418 of acitretin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "Rank 12: adapalene with relative risk of -50.418 of acitretin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "Rank 13: adapalene with relative risk of -50.418 of acitretin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó aclidinium *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: citalopram with relative risk of -6.655 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: rocuronium with relative risk of -7.347 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: trospium with relative risk of -8.446 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: cevimeline with relative risk of -8.446 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: disopyramide with relative risk of -22.513 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: disopyramide with relative risk of -22.513 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: disopyramide with relative risk of -22.513 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: tiotropium with relative risk of -26.071 of aclidinium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 9: oxybutynin with relative risk of -26.071 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: oxybutynin with relative risk of -26.071 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: oxybutynin with relative risk of -26.071 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: tiotropium with relative risk of -26.071 of aclidinium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 13: atropine with relative risk of -26.071 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: atropine with relative risk of -26.071 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: atropine with relative risk of -26.071 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: tiotropium with relative risk of -26.071 of aclidinium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 17: umeclidinium with relative risk of -26.071 of aclidinium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Chronic Obstructive Airway Disease,pulmonary\n",
      "Rank 18: umeclidinium with relative risk of -26.071 of aclidinium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Chronic Obstructive Airway Disease,pulmonary\n",
      "Rank 19: umeclidinium with relative risk of -26.071 of aclidinium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Chronic Obstructive Airway Disease,pulmonary\n",
      "Rank 20: olanzapine with relative risk of -31.027 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: olanzapine with relative risk of -31.027 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: olanzapine with relative risk of -31.027 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: olanzapine with relative risk of -31.027 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: olanzapine with relative risk of -31.027 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: amoxapine with relative risk of -31.471 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: amoxapine with relative risk of -31.471 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: amoxapine with relative risk of -31.471 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: amoxapine with relative risk of -31.471 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: amoxapine with relative risk of -31.471 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: loxapine with relative risk of -33.275 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: loxapine with relative risk of -33.275 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: loxapine with relative risk of -33.275 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: loxapine with relative risk of -33.275 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: loxapine with relative risk of -33.275 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: clozapine with relative risk of -33.444 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: clozapine with relative risk of -33.444 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: clozapine with relative risk of -33.444 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: clozapine with relative risk of -33.444 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: clozapine with relative risk of -33.444 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: quetiapine with relative risk of -33.991 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: quetiapine with relative risk of -33.991 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: quetiapine with relative risk of -33.991 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: quetiapine with relative risk of -33.991 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: quetiapine with relative risk of -33.991 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: ziprasidone with relative risk of -34.390 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: ziprasidone with relative risk of -34.390 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: ziprasidone with relative risk of -34.390 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: ziprasidone with relative risk of -34.390 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: ziprasidone with relative risk of -34.390 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: aripiprazole with relative risk of -34.606 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: aripiprazole with relative risk of -34.606 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: aripiprazole with relative risk of -34.606 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: aripiprazole with relative risk of -34.606 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: aripiprazole with relative risk of -34.606 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: paroxetine with relative risk of -41.462 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: paroxetine with relative risk of -41.462 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: paroxetine with relative risk of -41.462 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: paroxetine with relative risk of -41.462 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: paroxetine with relative risk of -41.462 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: scopolamine with relative risk of -43.691 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: scopolamine with relative risk of -43.691 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: scopolamine with relative risk of -43.691 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: scopolamine with relative risk of -43.691 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: scopolamine with relative risk of -43.691 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: tolterodine with relative risk of -45.486 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: tolterodine with relative risk of -45.486 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: tolterodine with relative risk of -45.486 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: tolterodine with relative risk of -45.486 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: tolterodine with relative risk of -45.486 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: glycopyrrolate with relative risk of -45.486 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: pilocarpine with relative risk of -45.486 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: glycopyrrolate with relative risk of -45.486 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: glycopyrrolate with relative risk of -45.486 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: glycopyrrolate with relative risk of -45.486 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: ipratropium with relative risk of -45.486 of aclidinium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 76: ipratropium with relative risk of -45.486 of aclidinium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 77: ipratropium with relative risk of -45.486 of aclidinium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 78: ipratropium with relative risk of -45.486 of aclidinium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 79: ipratropium with relative risk of -45.486 of aclidinium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 80: glycopyrrolate with relative risk of -45.486 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: fesoterodine with relative risk of -45.486 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: fesoterodine with relative risk of -45.486 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: fesoterodine with relative risk of -45.486 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: fesoterodine with relative risk of -45.486 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: fesoterodine with relative risk of -45.486 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: darifenacin with relative risk of -45.486 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: darifenacin with relative risk of -45.486 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: darifenacin with relative risk of -45.486 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: darifenacin with relative risk of -45.486 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: darifenacin with relative risk of -45.486 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: pilocarpine with relative risk of -45.486 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: pilocarpine with relative risk of -45.486 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: pilocarpine with relative risk of -45.486 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: pilocarpine with relative risk of -45.486 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target actinomycin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó acyclovir *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cladribine with relative risk of -7.752 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: didanosine with relative risk of -10.054 of acyclovir | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó adapalene *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bexarotene with relative risk of -25.378 of adapalene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bexarotene with relative risk of -25.378 of adapalene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: bexarotene with relative risk of -25.378 of adapalene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: tazarotene with relative risk of -34.332 of adapalene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Acne Vulgaris,dermatology\n",
      "Rank 5: tazarotene with relative risk of -34.332 of adapalene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Acne Vulgaris,dermatology\n",
      "Rank 6: tazarotene with relative risk of -34.332 of adapalene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Acne Vulgaris,dermatology\n",
      "Rank 7: tazarotene with relative risk of -34.332 of adapalene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Acne Vulgaris,dermatology\n",
      "Rank 8: acitretin with relative risk of -50.418 of adapalene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "Rank 9: acitretin with relative risk of -50.418 of adapalene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "Rank 10: acitretin with relative risk of -50.418 of adapalene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "Rank 11: acitretin with relative risk of -50.418 of adapalene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "Rank 12: acitretin with relative risk of -50.418 of adapalene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "Rank 13: acitretin with relative risk of -50.418 of adapalene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target adefovir not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó adenosine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: gabapentin with relative risk of -4.591 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: nicardipine with relative risk of -8.109 of adenosine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 3: pentoxifylline with relative risk of -16.619 of adenosine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 4: pentoxifylline with relative risk of -16.619 of adenosine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 5: pentoxifylline with relative risk of -16.619 of adenosine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 6: caffeine with relative risk of -22.507 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: caffeine with relative risk of -22.507 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: caffeine with relative risk of -22.507 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: caffeine with relative risk of -22.507 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: aminophylline with relative risk of -27.280 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: aminophylline with relative risk of -27.280 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: aminophylline with relative risk of -27.280 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: aminophylline with relative risk of -27.280 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: regadenoson with relative risk of -33.484 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: regadenoson with relative risk of -33.484 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: regadenoson with relative risk of -33.484 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: regadenoson with relative risk of -33.484 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó afatinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: lidocaine with relative risk of -7.570 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: erlotinib with relative risk of -8.263 of afatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 3: gefitinib with relative risk of -8.956 of afatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Epidermal growth factor receptor positive non-small cell lung cancer,oncology\n",
      "Rank 4: lapatinib with relative risk of -18.316 of afatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 5: lapatinib with relative risk of -18.316 of afatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 6: vandetanib with relative risk of -20.508 of afatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 7: vandetanib with relative risk of -20.508 of afatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 8: vandetanib with relative risk of -20.508 of afatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó albendazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: podophyllotoxin with relative risk of -7.570 of albendazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 2: vincristine with relative risk of -8.263 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ixabepilone with relative risk of -8.956 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: paclitaxel with relative risk of -21.034 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: paclitaxel with relative risk of -21.034 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: paclitaxel with relative risk of -21.034 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: docetaxel with relative risk of -21.181 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: docetaxel with relative risk of -21.181 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: docetaxel with relative risk of -21.181 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: colchicine with relative risk of -21.667 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: colchicine with relative risk of -21.667 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: colchicine with relative risk of -21.667 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: vinorelbine with relative risk of -22.044 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: vinorelbine with relative risk of -22.044 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: cabazitaxel with relative risk of -22.044 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: cabazitaxel with relative risk of -22.044 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: cabazitaxel with relative risk of -22.044 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: vinorelbine with relative risk of -22.044 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó alendronate *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibandronate with relative risk of -8.446 of alendronate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: orthopedics\n",
      "Rank 2: pamidronate with relative risk of -8.446 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: risedronate with relative risk of -8.446 of alendronate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: orthopedics\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target alfentanil not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó alfuzosin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: verapamil with relative risk of -4.456 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: diclofenac with relative risk of -5.097 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: iloperidone with relative risk of -5.097 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: quinidine with relative risk of -5.297 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: trazodone with relative risk of -5.414 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: disopyramide with relative risk of -5.547 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: citalopram with relative risk of -5.701 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: apraclonidine with relative risk of -6.105 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: labetalol with relative risk of -6.392 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: flecainide with relative risk of -6.392 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: levetiracetam with relative risk of -6.392 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: rilpivirine with relative risk of -6.797 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: bupivacaine with relative risk of -6.797 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: ropivacaine with relative risk of -7.490 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: fosphenytoin with relative risk of -7.490 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: olanzapine with relative risk of -8.012 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: olanzapine with relative risk of -8.012 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: loxapine with relative risk of -8.868 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: loxapine with relative risk of -8.868 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ziprasidone with relative risk of -9.287 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ziprasidone with relative risk of -9.287 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: aripiprazole with relative risk of -9.367 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: aripiprazole with relative risk of -9.367 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "Drug target aliskiren not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó allopurinol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: febuxostat with relative risk of -10.054 of allopurinol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hyperuricemia\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó almotriptan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: amoxapine with relative risk of -5.557 of almotriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: penbutolol with relative risk of -7.976 of almotriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: olanzapine with relative risk of -12.348 of almotriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: olanzapine with relative risk of -12.348 of almotriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: loxapine with relative risk of -13.211 of almotriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: loxapine with relative risk of -13.211 of almotriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: clozapine with relative risk of -13.273 of almotriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: clozapine with relative risk of -13.273 of almotriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: quetiapine with relative risk of -13.479 of almotriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: quetiapine with relative risk of -13.479 of almotriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: ziprasidone with relative risk of -13.633 of almotriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: ziprasidone with relative risk of -13.633 of almotriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: aripiprazole with relative risk of -13.711 of almotriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: aripiprazole with relative risk of -13.711 of almotriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: risperidone with relative risk of -14.169 of almotriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: risperidone with relative risk of -14.169 of almotriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: cabergoline with relative risk of -14.169 of almotriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: cabergoline with relative risk of -14.169 of almotriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: bromocriptine with relative risk of -14.274 of almotriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: bromocriptine with relative risk of -14.274 of almotriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó alogliptin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# runs calc_relative_risk for every drug on our dataset \n",
    "\n",
    "for drug_name in drugs:\n",
    "    \n",
    "    try:\n",
    "        main(drug_name)\n",
    "    except:\n",
    "        print('')\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Test if candidate drugs for repurposing also appear in our drug-drug interaction network as neighbors"
   ]
  }
 ],
 "metadata": {
  "interpreter": {
   "hash": "dcacb0086e9a4f4eabd41c33bf4faac5ea0a3337ed3f5eff0680afa930572c04"
  },
  "kernelspec": {
   "display_name": "Python 3.9.7 64-bit",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.7"
  },
  "orig_nbformat": 4
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
